Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple A/H3N2 strains with or without the B/Yamagata strain in US adults aged 50–75 years: a phase 1/2, open-label, randomised trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Infectious Diseases

Topics

Biology

Epidemiology

Medicine

Immunology

Pathology

Show all topics

DOI

10.1016/s1473-3099(24)00493-6